β-Blocker therapy for heart failure
Monte L. Slatton, Eric J. Eichhorn
Abstract
Monte L. Slatton, Eric J. Eichhorn
Abstract
Despite therapy with diuretics, digoxin, and angiotensin-converting enzyme inhibitors, congestive heart failure remains an important health problem with high mortality, and it is clear that new treatments for heart failure are needed. Evidence from basic research, animal studies, and clinical human trials indicates that high adrenergic tone in patients with heart failure is deleterious; furthermore, the deleterious effects are partially reversible with beta-adrenergic blockade. This article reviews the recent developments in our understanding of the pathophysiology of heart failure and the recent data concerning the treatment of heart failure with beta-blocking agents.
OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Despite therapy with diuretics, digoxin, and angiotensin-converting enzyme inhibitors, congestive heart failure remains an important health problem with high mortality, and it is clear that new treatments for heart failure are needed. Evidence from basic research, animal studies, and clinical human trials indicates that high adrenergic tone in patients with heart failure is deleterious; furthermore, the deleterious effects are partially reversible with beta-adrenergic blockade. This article reviews the recent developments in our understanding of the pathophysiology of heart failure and the recent data concerning the treatment of heart failure with beta-blocking agents.
Key concepts: Medicine, Heart failure, Digoxin, Cardiology, Blockade, Intensive care medicine, Clinical trial, Internal medicine